An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Breast Cancer Content
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
Experts in the management of breast cancer discuss new and emerging agents for HER2-negative metastatic breast cancer.
- Discuss how novel treatments may be integrated into clinical practice for HER2-negative mBC, including optimal patient identification and treatment sequencing
- Identify considerations surrounding the use of ADCs and evaluate how safety management may support adherence in patients with HER2-negative mBC
- Evaluate the latest data for novel and emerging ADCs in managing HER2-negative mBC
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
touchREVIEWS in Oncology & Haematology. 2023;19(1):Online ahead of journal publication
Breast cancer is the most common cancer among women worldwide, and more than a fifth of those diagnosed will develop incurable metastatic disease.1 Molecular testing to investigate genetic and genomic variation is essential to identify the most effective treatment plans for patients. Treatment options available for patients with breast cancer are directed through the receptor status […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]
Navigating HRT and cancer risk: PrEvCan | Celia Diez de los Rios
This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT). Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of […]
Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios
The relationship between breastfeeding and a reduction in cancer risk is the focus of the PrEvCan Campaign, this July. Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer. In this interview […]
Trastuzumab Deruxtecan for the Treatment of HER2-positive Breast Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(1):6–10 DOI: https://doi.org/10.17925/OHR.2023.19.1.6
Trastuzumab deruxtecan (T-DXd) is a highly effective drug for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced recurrent breast cancer. It was approved by the US Food and Drug Admninistration even though it had only been through a phase II study. It has attracted a great deal of attention among oncologists, and many clinical trials have been conducted. This article reviews reports of […]
Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All
touchREVIEWS in Oncology & Haematology. 2023;19(1):11-16 DOI: https://doi.org/10.17925/OHR.2023.19.1.11
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all breast cancers.1 This breast cancer subtype was historically associated with poor outcomes; however, the development of HER2-directed therapies has dramatically improved outcomes for patients with both early and advanced HER2+ disease.2 Currently, there are several types of HER2-targeted agents approved for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!